tgfβ1

TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research [1].

TGFβ1-IN-3 is a diarylhydrazone derivative with inhibitory effects on fibroblast activation and proliferation.TGFβ1-IN-3 is a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF).

TGFβ1-IN-1 is an orally active TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrotic markers (α-SMA and fibronectin) and can be used for the study of cancer and autoimmune diseases.

pm26TGF-β1 peptide, mimicking a portion of the human TGF-β1 molecule, demonstrates a high affinity for the TGF-β1 receptor. It exhibits potent anti-inflammatory properties without inducing neutrophils' chemoattraction [1] [2].

TGFβ-IN-1 is an antitumor growth and metastasis agent by inhibiting the transforming growth factor β signaling pathway.

pm26TGF-β1 TFA peptide is a synthetic peptide that emulates a segment of the human TGF-β1 molecule, demonstrating high affinity for the TGF-β1 receptor. It possesses potent anti-inflammatory capabilities while lacking the ability to attract neutrophils [1] [2].

TGFβR-IN-1 is a long-acting tumor-activated proagent of a TGFβR inhibitor.

Disitertide acetate (P144 acetate) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide acetate is also a PI3K inhibitor and an apoptosis inducer.

Fresolimumab (GC1008) is a specific human anti-transforming growth factor β monoclonal antibody that binds to the active forms of human TGFβ1, TGFβ2, and TGFβ3 and can be used to study focal segmental glomerulosclerosis and cancer in adults.

Linavonkibart (SRK 181) is a fully human antibody with high affinity for latent TGFβ1, selectively binding and inhibiting its activation. This compound is significant in the context of cancer [1].

Metelimumab (CAT-192), a human IgG4 monoclonal antibody, selectively neutralizes TGFβ1 [1].

Disitertide (P144) diammonium, a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor, is specifically engineered to prevent its receptor interaction. Additionally, it serves as a PI3K inhibitor and induces apoptosis, as evidenced by references [1] [2] [3] [4] [5].

Livmoniplimab (ABBV-151; ARGX-115), a potent humanized monoclonal antibody targeting LRRC32 (GARP)/TGFβ1, inhibits LRRC32-mediated activation of latent TGFβ1. This compound shows promise for cancer research [1].

RU-301 is a novel pan-tam inhibitor

Disitertide (P144) TFA is a peptide-based inhibitor of transforming growth factor-beta 1 (TGF-β1), specifically engineered to prevent its interaction with the receptor. Additionally, it functions as a PI3K inhibitor and promotes apoptosis, as supported by references [1] [2] [3] [4] [5].